ANTI-AGEING
63
The pivotal role of Bifidobacterium adolescentis
Marina Zhao, Yankie Yang – Jaka Biotech ABSTRACT
Biomenta BF with its unique active ingredient the Bifida Ferment Lysate, targets at slowing down cellular senescence by reducing nucleus damage, promoting HES1 and collagen I expression, enhancing mitochondrial activity, and inhibiting MMP3 expression. In this study, the anti-ageing effects of Bifida Ferment Lysate were validated by in vitro and clinical efficacy tests. The results indicate that Bifida Ferment Lysate effectively inhibits cellular senescence and delays the formation of wrinkles.
Ageing is a spontaneous and inevitable process of living things over time. The external manifestations are wrinkles, fine lines, and laxity in the face and other body parts, while cellular senescence is the prerequisite and main driving force of the physiological ageing process.1 The International Cell Senescence
Association states that cellular senescence is stimulated by stress signals and is present in a specific physiological process. When healthy cells are stimulated by stress signals, the overall cell viability varies, including a decrease in the overall cellular proliferation capacity and type I collagen expression, as well as causing molecular damage to the cell nucleus, decreasing organelle function, and affecting the cell secretion phenotypic varies in senescent cells.
Methodology The construction of UVA-P7 In order to study the effects of two major stress signals, genetic factors and photo factors, on cells, Jaka has constructed a cell model based on the ARTICELL platform that combines both endogenous ageing and photoageing— Photo- senescent cells UVA-P7. Photo-senescent cells UVA-P7 refer to
the cells cultured up to generation 7 using passaging and UVA irradiation. P refers to the passage number. Photo-senescent cells UVA-P7 and Endogenous senescent cells P7 (hereafter referred to as P7 and UVA-P7) were used to evaluate the anti-ageing efficacy of Bifida Ferment Lysate in in vitro experiments.
Acquisition of Bifida Ferment Lysate Bifidobacterium adolescentis is a dominant
www.personalcaremagazine.com Figure 1: Based on ARTICELL Platform achieved UVA-P7 November 2024 PERSONAL CARE
bacterium present in the gut of young individuals. Unlike other bifidobacterium, its expression abundance decreases particularly in older age groups. The Bifida Ferment Lysate from
Bifidobacterium adolescentum fermentation source was obtained through the use of BIO-Segferm and ND-Celbroken.
In vitro experiments Sample treatment P7 and UVA-P7 were used in this in vitro experiment to mimic the endogenous and photoageing states of human skin. Prior to inoculating them into 96-well plates, P6 and UVA-P6 were digested, subsequently labeled as P7 and UVA-P7 respectively, and then cultured for 24 hours. The following day, the old culture medium was discarded, and the wells were gently
washed once with PBS. Afterward, 200 μL of different samples were added to each well according to the test groups. These were gently mixed and further cultured for 24 to 72 hours in a 37°C, 5% CO2
incubator.
Overall senescent cells viability Cell activity was detected using the MTT staining.2
After culturing, the cells were washed
once with PBS. Then, 150 μL of MTT working solution was added to each well. After staining for three hours, the staining solution was discarded, and another 150 μL of DMSO was added to each well. The plates were shaken in the dark for ten
minutes at room temperature. Subsequently, the OD value was measured at 570 nm. Test time point: 24, 48 and 72 hours. The expression of type I collagen was detected by immunofluorescence staining.3
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
